Search
BCc1
go.drugbank.com/drugs/DB16504ExperimentalBCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.
Quinacrine
go.drugbank.com/drugs/DB01103InvestigationalIt has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. … An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.
CPD 923
go.drugbank.com/drugs/DB05856ExperimentalCPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Mocetinostat
go.drugbank.com/drugs/DB11830InvestigationalMocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.
AZD-6482
go.drugbank.com/drugs/DB14980InvestigationalAZD-6482 is under investigation in clinical trial NCT00688714 (Study to Investigate Safety and Tolerability of a Single Dose of AZD6482).
Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitorsLY-517717
go.drugbank.com/drugs/DB05713InvestigationalLY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
Isoxsuprine
go.drugbank.com/drugs/DB08941ApprovedWithdrawnIts vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
Thioredoxin
go.drugbank.com/drugs/DB11298ApprovedThioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in foods from animal and plant products. … It plays an essential role as an antioxidant in neutralizing food allergens and redox signalling. Allergens containing disulfide bonds are inactivated when reduced by thioredoxin.
Blonanserin
go.drugbank.com/drugs/DB09223InvestigationalBlonanserin is an atypical antipsychotic approved in Japan in January, 2008. … As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.